But weight loss did not fully account for the differences. Even when researchers limited their analysis to participants who had lost weight, GLP-1 users still reported significantly more nail problems than nonusers.

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said study author Dr. Charles Taïeb. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."

Indeed, roughly half of the medication users said they had experienced nail problems even before starting treatment. When the researchers accounted for existing skin conditions and nutritional deficiencies, some of the gaps between the groups shrank. Even so, nail detachment and discoloration remained about two to three times more common among GLP-1 users after these adjustments.

What about hair and scalp symptoms?

A companion study examining the same participants found similar patterns in hair and scalp health:

• Unusual hair loss: 50% of GLP-1 users versus 34% of nonusers
• Reduced hair volume or density: 42% versus 19%
• Hair loss that began after starting treatment: 26% versus 12%
• Scalp redness: roughly three times more frequent among users

Notably, hair loss rarely appeared on its own. Most users who reported shedding also had other scalp symptoms, including itching, redness, or flaking skin. That combination suggests inflammation may be playing a role, rather than rapid weight reduction alone.

"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," explained study author Dr. Bruno Halioua. "Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable. Taken together, our findings suggest that factors beyond weight loss alone may contribute to the hair, scalp and nail changes observed among GLP-1 users."

Should people taking these drugs be worried?

The researchers stressed awareness rather than alarm. "These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative," Dr. Halioua said. "Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy."

The studies also carry important limitations. Both were cross-sectional, meaning they captured participants' experiences at one point in time rather than following them over months or years. And the findings relied on symptoms reported by participants, not on standardized clinical examinations. As a result, the research can reveal patterns and associations, but it cannot prove that GLP-1 medications directly caused the reported nail, hair, or scalp problems.

The research team now plans prospective studies that will follow patients from the start of treatment, with standardized skin, hair, and nail examinations plus biological monitoring. The goal is to pin down when the changes first appear, what mechanisms drive them, and whether they fade over time. The research received institutional support from DUCRAY Laboratories (Pierre Fabre Group), a company specializing in dermatological and hair care products.